# Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer

> **NCT00453323** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 33 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00453323
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** 2009-12
- **Final completion:** 2010-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2010-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453323, "Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00453323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*